A computational study of the Warburg effect identifies metabolic targets inhibiting cancer migration by Yizhak, K. et al.
Article
A computational study of the Warburg effect
identifies metabolic targets inhibiting
cancer migration
Keren Yizhak1,*,†, Sylvia E Le Dévédec2,†, Vasiliki Maria Rogkoti2, Franziska Baenke3, Vincent C de Boer4,
Christian Frezza5, Almut Schulze3, Bob van de Water2,‡ & Eytan Ruppin1,6,‡,**
Abstract
Over the last decade, the field of cancer metabolism has mainly
focused on studying the role of tumorigenic metabolic rewiring
in supporting cancer proliferation. Here, we perform the first
genome-scale computational study of the metabolic underpin-
nings of cancer migration. We build genome-scale metabolic
models of the NCI-60 cell lines that capture the Warburg effect
(aerobic glycolysis) typically occurring in cancer cells. The extent
of the Warburg effect in each of these cell line models is quan-
tified by the ratio of glycolytic to oxidative ATP flux (AFR),
which is found to be highly positively associated with cancer
cell migration. We hence predicted that targeting genes that
mitigate the Warburg effect by reducing the AFR may specifi-
cally inhibit cancer migration. By testing the anti-migratory
effects of silencing such 17 top predicted genes in four breast
and lung cancer cell lines, we find that up to 13 of these novel
predictions significantly attenuate cell migration either in all or
one cell line only, while having almost no effect on cell prolifer-
ation. Furthermore, in accordance with the predictions, a signifi-
cant reduction is observed in the ratio between experimentally
measured ECAR and OCR levels following these perturbations.
Inhibiting anti-migratory targets is a promising future avenue in
treating cancer since it may decrease cytotoxic-related side
effects that plague current anti-proliferative treatments.
Furthermore, it may reduce cytotoxic-related clonal selection of
more aggressive cancer cells and the likelihood of emerging
resistance.
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Introduction
Altered tumor metabolism has become a generally regarded hall-
mark of cancer (Hanahan & Weinberg, 2011). The initial recognition
that metabolism is altered in cancer can be traced back to Otto
Warburg’s early studies, showing that transformed cells consume
glucose at an abnormally high rate and largely reduce it to lactate,
even in the presence of oxygen (Warburg, 1956). Over the last
decade, much of the field of cancer metabolism has focused on the
role of the Warburg effect in supporting cancer proliferation (Vander
Heiden et al, 2009). However, the role of this process in supporting
other fundamental cancer phenotypes such as cellular migration has
received far less attention.
Contemporary cytotoxic cancer treatment has been mainly
based on drugs that kill proliferating cells generally unselectively
and are therefore accompanied by many undesirable side effects.
Drug targets that can inhibit migration but leave cellular prolifer-
ation relatively spared may be able to avoid such side effects.
Such targets may have the additional benefit of reducing the
selection for more resistant clones that occurs due to the elimi-
nation of treatment-sensitive cells. The growing availability of
high-throughput measurements for a range of cancer cells
presents an opportunity to study a wider scope of dysregulated
metabolism across many different cancers. Here, we aim to
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integrate pertaining data with a genome-scale mechanistic model
of human metabolism to study the role of the Warburg effect in
tumor progression and its potential association with cellular
migration.
Genome-scale metabolic modeling is an increasingly widely
used computational framework for studying metabolism. Given
the genome-scale metabolic model (GSMM) of a species along-
side contextual information such as growth media and ‘omics’
data, one can obtain a fairly accurate prediction of numerous
metabolic phenotypes, including growth rates, nutrient uptake
rates, gene essentiality, and more (Covert et al, 2004). GSMMs
have been used for various applications (Oberhardt et al, 2009;
Chandrasekaran & Price, 2010; Jensen & Papin, 2010; Szappanos
et al, 2011; Wessely et al, 2011; Lerman et al, 2012; Nogales
et al, 2012; Schuetz et al, 2012) including drug discovery
(Trawick & Schilling, 2006; Oberhardt et al, 2013; Yizhak et al,
2013) and metabolic engineering (Burgard et al, 2003; Pharkya
et al, 2004). Over the last few years, GSMMs have been success-
fully used for modeling human metabolism as well (Duarte et al,
2007; Ma et al, 2007; Shlomi et al, 2008; Gille et al, 2010; Lewis
et al, 2010; Mardinoglu et al, 2013). Specifically, GSMM models
of cancer cells have been reconstructed and applied for predict-
ing selective drug targets, as well as for studying the role of
tumor suppressors and oxidative stress (Folger et al, 2011; Frezza
et al, 2011; Agren et al, 2012, 2014; Jerby et al, 2012; Goldstein
et al, 2013; Gatto et al, 2014). In the context of studying the
Warburg effect, the original human metabolic model does not
predict forced lactate secretion under maximal biomass produc-
tion rate, even when oxygen consumption rate equals zero.
This renders it unsuitable for studying the Warburg effect as is,
as already noted by (Shlomi et al, 2011). While the addition of
solvent capacity constraints has been shown to overcome this
hurdle in principle (Shlomi et al, 2011), this addition requires
enzymatic kinetic data which are still largely absent on a
genome-scale.
In this study, we utilize individual genome-scale metabolic
models tailored separately to each of the NCI-60 cancer cell lines
to study the role of the Warburg effect in supporting cancer cellu-
lar migratory capacity. We first test and validate the individual
models against both existing and novel bioenergetic experimental
data. Then, we examine the extent of the Warburg effect occur-
ring in a given cancer cell line, by quantifying the glycolytic to
oxidative ATP flux ratio (AFR). We find that the AFR is highly
positively correlated with cancer cell migration, emphasizing the
role of glycolytic flux in supporting the more aggressive meta-
static stages of tumor development. To determine whether a
causal relation exists between AFR levels and cell migration, we
predict gene silencing that reduce this ratio. These potential
targets are then filtered further to exclude those predicted to
result in cell lethality. Reassuringly, the predicted targets are
found to be significantly more highly expressed in metastatic and
high-grade breast cancer tumors. Experimental investigation of
the top predicted targets via siRNA-mediated knockdown shows
that a significant portion of them truly attenuate cancer cell
migration without inducing a lethal effect. Furthermore, in accor-
dance with the predictions, a significant reduction is observed in
the ratio between ECAR and OCR levels following these genes
silencing perturbations.
Results
Stoichiometric and flux capacity constraints successfully capture
the coupling of high cell proliferation rate to lactate secretion
across individual NCI-60 cancer models
As a starting point for this study, we developed a set of metabolic
models specific for each of the NCI-60 cell lines. We built these
models using a new algorithm we have recently developed termed
PRIME, for building individual models of cells from pertaining
omics data (Yizhak et al, submitted, Supplementary Information
and Supplementary Fig S1). PRIME uses the generic human model
as a scaffold and sets maximal flux capacity constraints over a
subset of its growth-associated reactions according to the expression
levels of their corresponding catalyzing enzymes in each of the
target cell lines.
An important hallmark of cancerous cells is the production of
lactate through the Warburg effect (Warburg, 1956). As a first step
in validating the basic function of our NCI-60 models, we assessed
whether maximizing biomass forces production of lactate, which
would signify proper coupling of biomass production with lactate
output as seen in cancer cells. We found that the models indeed
must secrete lactate under biomass maximization (Supplementary
Information and Supplementary Fig S2). Hence, in contrast to the
original generic model of human metabolism, they enable us to
systematically assess the extent of lactate secretion and study the
Warburg effect across a wide range of cancer cell lines without
needing to add (mostly unknown) solvent capacity constraints, thus
identifying its functional correlates on a genome scale.
Comparing predicted versus experimentally measured
bioenergetics capacity
We compared the predicted lactate secretion rates across all cell
lines to those measured experimentally by Jain et al (Jain et al,
2012), obtaining a moderate but significant correlation (Spearman
correlation R = 0.36, P-value = 5.7e3, Fig 1A, Materials and Meth-
ods). To further test the models’ performance under different envi-
ronmental conditions, we measured lactate secretion rates in four
breast cancer cell lines, T47D, MCF7, BT549, and Hs578T (Supple-
mentary Dataset S1), under both normoxic and hypoxic conditions
(see Materials and Methods). Utilizing the corresponding cell line
models from the NCI-60 set, we found a high correlation between
measured and predicted lactate secretion levels across both condi-
tions (Spearman correlation R = 0.95, P-value = 1.1e3, Fig 1B).
The ratio of glycolytic versus oxidative capacity in a cell can be
quantified using its extracellular acidification rate (ECAR, a proxy of
lactate secretion) and its oxygen consumption rate (OCR). To
further examine how well our cell line models capture measured
Warburg-related activity in response to genetic perturbations, we
utilized measured ECAR and OCR levels in response to perturba-
tions in two NCI-60 lung cancer cell lines (A549 and H460), and
compared the results to predictions from our models (Materials and
Methods) (Wu et al, 2007). Qualitatively similar ECAR and OCR
changes are found in response to various enzymatic perturbations
along the glycolytic pathway. Specifically, increased glycolytic inhi-
bition resulted in reduced ECAR and elevated OCR levels in both
cells, while the maximum cellular respiration increase in H460 cells
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observed after all glycolysis inhibitors was lower than the corre-
sponding increase in A549 cells (Fig 1C).
Quantifying the Warburg effect and its relation to proliferation
and migration across the NCI-60 cell lines
While ECAR and OCR are the commonly used measures for experi-
mentally quantifying the bioenergetic capacity of the cell and thus
the Warburg effect, the genome-wide scope of GSMMs enables us to
examine other putative measures as well. One promising such
measure we examined is the ratio between the ATP flux rate in the
glycolysis versus its flux rate in OXPHOS (AFR). Clearly, higher AFR
values denote more ‘Warburgian’ cell lines and vice versa. A
comparison of our new AFR metric versus the aforementioned
state-of-the-art ECAR/OCR ratio (EOR) (Materials and Methods and
Supplementary Dataset S2) showed a significant correlation across
the NCI-60 models (Spearman correlation R = 0.66, P-value = 2e8).
Testing both measures using a genome-wide NCI-60 drug response
dataset (Scherf et al, 2000), we find that the model-predicted wild-
type AFR levels across all cell line models are significantly corre-
lated (Spearman P-value < 0.05; FDR corrected with a = 0.05) with
Gi50 values of 30% of the compounds across these cell lines
(empiric P-value < 9.9e4), whereas the model-predicted EOR
measure accomplish this task for only 19% of the compounds
(Materials and Methods). Interestingly, we find that out of the 30%
AFR-Gi50-correlated compounds, 97% are positively correlated,
suggesting that the more ‘Warburgian’ cell lines are less responsive
and therefore require higher dosage of compound to suppress their
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Figure 1. A comparison between experimental and predicted in silicomeasurements of lactate secretion (or ECAR) and OCR across different cancer cell lines.
A Measured versus predicted lactate secretion rates across the 59 cell lines available at Jain et al (2012).
B Measured versus predicted lactate secretion rates in hypoxic (red) and normoxic (blue) conditions for four breast cancer cell lines: T47D, MCF7, BT549, and Hs578T.
Bars represent the measured lactate secretion rates and the line represents the corresponding predicted rates. Error bars represent SD; number of samples for
experimental data (bars) is n = 7; number of samples for predicted data (line) is n = 1000.
C Predicted ECAR and OCR by the A549 and H460 cell line models following inhibitory perturbations in the glycolytic pathway. The models predictions show a decrease
in ECAR (red line) and an increase in OCR (blue line). As found experimentally, the predicted OCR increase in H460 cells is lower than that found for A549 cells. The
x-axes represent the level of inhibition imposed, starting from a zero to a maximal inhibition (Materials and Methods). The specific perturbations include 3BpRA that
inhibits the enzyme hexokinase 2; Iodoacetate that inhibits the enzyme glycerol-3-phosphate dehydrogenase; Fluoride that inhibits the enzyme enolase; and
Oxamate that inhibits the enzyme lactate dehydrogenase.
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growth. The effect of most of these compounds is also negatively
correlated with the cells’ growth rates, suggesting that slowly
proliferating cells are more resistant to treatment (similar results were
previously shown for compounds targeting cell growth (Penault-
Llorca et al, 2009; Vincent-Salomon et al, 2004)). Interestingly, the
response to many compounds in this dataset shows a significant
association with the AFR measure while having no association with
the cells’ growth rate. 133 such compounds were identified (Supple-
mentary Dataset S3), possibly suggesting that their mechanism
might be related to the Warburg level of the cells rather than to their
proliferation. Finally, predicted AFR values correctly separate
between epithelial and mesenchymal breast cancer cell lines (with
the more aggressive mesenchymal cell lines exhibiting larger
Warburg effect (Sarrio et al, 2008), Fig 2A). Once again, the AFR
was more predictive of this experimental observation than the EOR
(Supplementary Dataset S2).
We next turned to our primary objective of examining the rela-
tion between the Warburg effect and tumor proliferation and migra-
tion. To this end, we experimentally measured the migration speed
of six NCI-60 breast cancer cell lines (Fig 2B and C, Materials and
Methods, Supplementary Fig S3, and Supplementary Dataset S2)
and utilized publically available measured growth rates for these
cell lines. While the AFR correlates markedly negatively with cell
growth rate (Spearman correlation of R = 0.55, P-value = 4.53e6,
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Figure 2. Association between AFR levels and cell proliferation and migration.
A The 20 cell lines that are predicted to exhibit the Warburg effect to the greatest/least extent according to the AFR measure. The x-axis and y-axis represent the mean
and SD of the normalized ATP flux rate in glycolysis and OXPHOS, respectively (Materials and Methods). The AFR measure correctly separates between mesenchymal
(orange) and epithelial cell lines (green), showing that the former (which are known to be more aggressive) have higher AFR levels.
B We analyzed a panel of six breast cancer cell lines for their migration capacity using live cell imaging. Differential Interference Contrast (DIC) images of the six cell
lines in the order of their respective migration speed (from low to high), scale bar is 100 lm (Materials and Methods).
C The average migration speed of cells followed for 12 h in complete medium. Error bars represent SEM; the number of samples is between n = 100 and n = 200.
D The correlation of predicted model-based EOR and AFR measures to growth and migration rates measured experimentally. Both measures represent a negative
correlation with growth and a positive correlation with migration rates. Significant results (P-value < 0.05) are marked with an asterisk.
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Fig 2D and Supplementary Table S1), it correlates even more
strongly in the positive direction with cancer cell migration
(Spearman correlation of R = 0.88, P-value = 0.03, Fig 2D and
Supplementary Table S1). Controlling for the cell lines’ measured
growth rates, this correlation becomes even more significant (partial
Spearman correlation of R = 0.96, P-value = 7e3, Supplementary
Table S1). Overall, this finding suggests that glycolytic flux correlates
with migration rather than with growth, while OXPHOS flux exhibits
the opposite behavior. A similar association between lactate secretion
and growth rate has been recently found in an experimental study
by Jain et al (Jain et al, 2012) across the entire NCI-60 collection
(Spearman correlation of R = 0.22, P = 0.09). Furthermore,
previous studies have shown that high concentrations of lactate
correlate with a high incidence of distant metastasis (Hirschhaeuser
et al, 2011). The overall picture portrayed by these correlations is that
while glycolytic carbon diverted to biosynthetic pathways may
support cell proliferation, non-diverted glycolytic carbon supports cell
migration and metastasis (Supplementary Fig S4).
Predicting drug targets that revert the AFR and hence may
inhibit cancer migration
The congruence between AFR levels and disease severity led us to
ask if we could build upon this association to identify potential new
drug targets. We searched for drug targets predicted to reduce the
AFR ratio by simulating the knockout of each metabolic reaction
across the NCI-60 models, and examining the effects of the knock-
outs on biomass production, lactate secretion, and the AFR. As
lactate secretion is a basic indicator of the Warburg effect, we first
identified a set of 113 reactions whose knockout is predicted to
abolish lactate secretion rate in all cancer cell lines under biomass
maximization. Interestingly, the set of enzymes catalyzing these
reactions is significantly more highly expressed in the NCI-60 cell
lines than the background metabolic genes (one-sided Wilcoxon
P-value < 1.6e8), indicating the potential oncogenic nature of
these genes.
To avoid selecting for drug-resistant clones it would be advanta-
geous to develop drugs that reduce the virulence of cancer cells but
avoid killing them. The knockout of 12 of 113 lactate-reducing reac-
tions reduces the AFR but relatively spares biomass production
(Materials and Methods and Supplementary Table S2). Importantly,
the knockout of these 12 reactions according to models of healthy
lymphoblast cells built by PRIME (Choy et al, 2008) also spares
their biomass production (Materials and Methods). Moreover, we
found that none of the lymphoblast cell lines show the forced lactate
secretion that is observed in cancer cells. While the Warburg effect
is sometimes referred in the literature as occurring in highly prolifer-
ating cells in general, our analysis finds that this phenomenon is
apparently more prominent in cancer cells, at least with regard to
the lymphoblastoid cell population studied here.
The final list of predicted gene targets includes 17 metabolic
enzymes that are associated with the final 12 reactions, spanning
glycolysis, serine, and methionine metabolism (Fig 3A). 10 of the
predicted targets have significantly higher expression levels in meta-
static versus non-metastatic breast cancer patients (Chang et al,
2005) (one-sided Wilcoxon P-value < 0.05, Fig 3B). Moreover, 9 of
the predicted targets exhibit higher expression levels in grade 3
tumors than in grade 1 tumors (Miller et al, 2005) (one-sided
Wilcoxon P-value < 0.05, Fig 3C). Finally, lower expression of nine
of the predicted targets is significantly associated with improved
long-term survival (Curtis et al, 2012) (log-rank P-value < 0.05,
Fig 3D), testifying for their potential role as therapeutic targets. All
P-values are corrected for multiple hypothesis using FDR with a = 0.05.
siRNA-mediated gene knockdown experiments testing the
predicted targets
To experimentally test our predictions we silenced the 17 predicted
AFR-reducing genes and examined their phenotypic effects in the
MDA-MB-231, MDA-MB-435, BT549, and A549 cell lines. Knock-
down experiments were performed with SmartPools from Dharma-
con using a live cell migration and fixed proliferation assays
(Materials and Methods). 8–13 out of the 17 enzymes (8–10 out of
12 metabolic reactions) were found to significantly attenuate migra-
tion speed in each cell line (two-sided t-test P-value < 0.05, FDR
corrected with a = 0.05, Fig 4, Materials and Methods and Supple-
mentary Dataset S4). This result is highly significant as only 17% of
the metabolic genes were found to impair cell migration in a siRNA
screen of 190 metabolic genes (Fokkelman M, Rogkoti VM et al,
unpublished data, Bernoulli P-value in the range of 3.9e3 and
1.18e7). Of note, the association between the gene expression of
the predicted targets and the measured migration speed is insignifi-
cant for all targets but one, testifying for the inherent value of our
model-based prediction analysis (Supplementary Table S3). It
should also be noted that the knockdown of the three splices of the
enolase gene have almost no significant effect on these cells’ migra-
tion speed, possibly because of isoenzymes backup mechanisms.
Importantly, most of the gene knockdown experiments do not
manifest any significant effects on cell proliferation (Fig 4). In
accordance with the findings of Simpson et al (Simpson et al,
2008), we found that the correlation between the reduction in
migration speed and reduction in proliferation rate is mostly
insignificant (Supplementary Dataset S4), suggesting that the
reduced migration observed is not simply a consequence of
common mechanisms hindering proliferation, but rather that it
occurs due to the disruption of distinct migratory-associated
metabolic pathways.
ECAR and OCR levels following selected gene silencing
To further study the association between reduced AFR levels and
impaired cell migration we used the Seahorse XF96 extracellular
flux analyzer to measure both ECAR and OCR fluxes in the MDA-
MB-231 cell line, following knockdown of a selected group of targets
(Materials and Methods and Supplementary Fig S6). As the AFR
measure is very difficult to measure experimentally, we tested the
conventionally measured EOR (ECAR/OCR) as its proxy. We
focused on a subset of seven genes (Fig 5) whose knockdown is
predicted to have the highest effect on cell migration and span all
three predicted metabolic pathways. As shown in Fig 5, a significant
EOR reduction versus the control is found for all seven examined
genes (two-sided t-test P-value < 0.05, FDR corrected with a = 0.05,
Materials and Methods and Supplementary Table S4). The silencing
of the four glycolytic genes (HK2, PGAM1, PGK2, and GAPDH)
results in both decreased ECAR and increased OCR levels, while
the silencing of the serine- and methionine-associated genes
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(PSPH, AHCY, and PHGDH) results with decreased ECAR solely
(Fig 5A). Furthermore, a matching significant difference in
experimentally measured EOR levels is found between the lowest and
highest AFR-reducing genes (one-sided Wilcoxon P-value = 0.05).
Overall, taken together our results testify that, as predicted, the
knockdown of the top-ranked genes results in attenuated cell
migration that is accompanied by reduced EOR and AFR levels.
Discussion
In this study we explored the role of the Warburg effect in support-
ing tumor migration, going beyond recent investigations focusing on
its role in assisting cancer proliferation. A model-based investigation
across cancer cell lines shows that the ratio between glycolytic and
oxidative ATP flux rate is significantly associated with cancer migra-
tory behavior. Gene silencing perturbations predicted to reduce this
ratio were indeed found to attenuate cell migration, and result with
a significant reduction in ECAR to OCR levels. Of note, our modeling
approach relies on gene expression differences between the cells
and does not take into account specific uptake rates. It is therefore
more suited for capturing qualitative rather than exact quantitative
differences between the cells, as demonstrated throughout the
paper. Moreover, the lion share of our analysis is focused on the
simulations of perturbations where specific uptake rates are not
available. Nonetheless, utilizing such uptake measurements can
significantly increase the correlation to the measured lactate rates
(Spearman correlation R = 0.67, P-value = 1.5e8), suggesting that
uptake rates measurements under perturbation states can signifi-
cantly increase the models’ prediction power.
Our AFR measure is conceptually analogous to a bioenergetic
(BEC) index previously introduced by Cuezva et al (Cuezva et al,
2002). In that study, the ratio between the expression of the glyco-
lytic enzyme glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
Glucose
G6P
F6P
FBP
G3PDHAP
1,3BPG
3PG
2PG
PEP
PyruvateLactate
Gln
Pyruvate
Ac-CoA
To Pentose
Phosphate Pathway
R5P
TCA
Cycle
Glycolysis
Serine
Glycine
mTHF
THF
HK2
PKM
GAPDH
TPI1
PGAM
PGK
3PHP
NAD NADH
PHGDH
SerineP-Serine
α-kgGlu
PSAT1 PSPH
L-Met adenosy
l-Met
MAT1/2
Serine 
Biosynthesis
Methionine 
Metabolism
ENO
adenosy
l-hcys
adn + Hcys
AHCY/AHCYL
A
P = 5.34e-4
P = 3.8e-5
P = 1.08e-7
P = 2.4e-3
P = 2.69e-5
P = 4.47e-5
P = 2.2e-6
P = 4.3e-4
P = 1.6e-2
P = 1.4e-2
P = 5.34e-5
P = 9.8e-3
P = 8.52e-5
P = 4.05e-4
P = 1.2-3
P = 2.78e-8
P = 7.08e-13
P = 4.61e-7
P = 1.83e-4
P = 4.61e-8
P = 1.96e-6
P = 6.08e-4
P = 6.12e-5
P = 1.86e-5
P = 3.75e-4
P = 1.5e-3
P = 1.1e-4
P = 2.85e-4
B
C
D
Figure 3. Gene targets that are predicted to reduce the AFR and their association with prognostic markers of breast cancer patients.
A A schematic representation of the 12 predicted gene targets, marked in red.
B Ten predicted targets that show a significantly higher expression in metastatic versus non-metastatic tumor samples (n = 295).
C Nine predicted targets that show a significantly higher expression in grade 3 versus grade 1 tumor samples (n = 236).
D Nine predicted targets whose lower expression is significantly associated with improved long-term survival (n = 1568).
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and the b-catalytic subunit of ATP synthase forming the BEC index
was found to have a prognostic value in assessing the clinical
outcome of patients with early-stage colorectal carcinomas. The
AFR measure and the BEC index (as computed by its corresponding
RNA levels) are significantly correlated (Spearman R = 0.58,
P-value = 1.6e6) across the NCI-60 cell lines, and the BEC index is
perfectly correlated with migration speed across the six breast
cancer cell lines (Spearman R = 1, P-value = 2.8e3). However, the
BEC index has inferior performance in predicting drug response
(Supplementary Table S1).
The finding that enhanced glycolytic activity plays a key role in
cancer cell migration is also in line with a very recent study by
De Bock et al, showing that glycolysis is the major source of ATP
production in endothelial cells and that the silencing of the glyco-
lytic regulator PFKFB3 impairs the cell migration capacity and inter-
feres with vessel sprouting (De Bock et al, 2013). In addition,
silencing of PFKFB3 was shown to suppress cell proliferation in
about 50% (De Bock et al, 2013). Overall, the results presented in
this study, as well as findings reported by others (Simpson et al,
2008), suggest that proliferation and migration are not mutually
exclusive, and the effect of potential targets on both processes
should be carefully examined.
Some of our predicted targets have been previously studied in
the context of cell proliferation as well (Cheong et al, 2012).
Possemato et al (Possemato et al, 2011) have showed that suppres-
sion of PHGDH in cell lines with elevated PHGDH expression, but not
Figure 4. Normalized to control mean speed per SmartPool gene silencing of the predicted targets.
A–D The four different cell lines that were analyzed: MDA-MB-231, MDA-MB-435s, BT549, and A549. Significant results (two-sided t-test, P-value < 0.05 after correcting
for multiple hypothesis using FDR with a = 0.05) are marked with an asterisk. Two different controls are used: (1) non-targeting siRNA (= negative control); and (2)
a positive control DNM2 which is known to block both migration and proliferation (Ezratty et al, 2005). Left panel shows migration speed and right panel shows
nuclear count. Error bars represent SD; the number of samples is n = 3.
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in those without, inhibits cell proliferation. Accordingly, as PHGDH
is not amplified in the cell line MDA-MB-231 which was examined
in both studies, its suppression is indeed non-lethal. However, we
show that its suppression significantly attenuates cell migration,
suggesting that metabolic enzymes can promote different cancerous
phenotypes in different cancer cells.
Remarkably, analyzing the model-predicted flux rates has
successfully uncovered a fundamental association between the AFR
and cancer migration, even given the relatively small set of cell lines
for which migration was measured. Our analysis has also revealed
other potential associations between individual fluxes and cell
migration (Supplementary Fig S4). However, future studies measur-
ing cellular migration data across a much wider array of cell lines
(of the order for which we already have proliferation data) are
needed to determine the actual significance of these potential leads.
As this study has shown, cellular proliferation and migration have
distinct underlying metabolite correlates; understanding the meta-
bolic correlates that are strongly associated with cell migration may
lead to new anti-metastatic treatment opportunities. It is important
to note, however, that while the inhibition of migration alone might
be a good strategy for avoiding the adverse side effects of cytotoxic
treatment, cell migration is a crucial process also in normal physiol-
ogy, for instance, in immune response and tissue repair (Fo¨rster
et al, 1999; Ridley et al, 2003). Therefore, future anti-migratory
drugs may pose different drug selectivity challenges that should be
carefully addressed in the future studies. Irrespectively, they may
result in lesser clonal selection, and as a result, their usage may be
accompanied with lesser rate of emergence of drug-resistant clones.
Materials and Methods
Computational methods
Genome-scale metabolic modeling (GSSM)
A metabolic network consisting of m metabolites and n reactions
can be represented by a stoichiometric matrix S, where the entry Sij
represents the stoichiometric coefficient of metabolite i in reaction j
(Price et al, 2004). A CBM model imposes mass balance, directional-
ity, and flux capacity constraints on the space of possible fluxes in
the metabolic network’s reactions through a set of linear equations:
Sv ¼ 0 (1)
vmin v vmax (2)
where v stands for the flux vector for all of the reactions in the
model (i.e. the flux distribution). The exchange of metabolites with
the environment is represented as a set of exchange (transport)
reactions, enabling a pre-defined set of metabolites to be either
taken up or secreted from the growth media. The steady-state
assumption represented in equation (1) constrains the production
rate of each metabolite to be equal to its consumption rate. Enzy-
matic directionality and flux capacity constraints define lower and
upper bounds on the fluxes and are embedded in equation (2).
In the following, flux vectors satisfying these conditions will
be referred to as feasible steady-state flux distributions. Gene
knockouts are simulated by constraining the flux through the
Figure 5. ECAR and OCR levels of top predicted gene targets.
A Mean and SEM (normalized to nuclear count) ECAR and OCR levels after silencing of seven different genes (HK2, PGAM1, PGK2, GAPDH, PSPH, AHCY, and PHGDH)
compared to the control. Silencing of the four glycolytic genes results in both a decrease in ECAR levels (x-axis) and an increase in OCR levels (y-axis), while the
serine- and methionine-associated genes show only a decrease in ECAR levels. Error bars represent SEM. The number of samples is n = 18.
B Mean and SD of computed ECAR/OCR (EOR) levels for control and selected gene silencing (Materials and Methods). For all genes a significant reduction in EOR levels
is observed. Error bars represent SD. The number of samples is n = 18.
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corresponding metabolic reaction to zero. The biomass function
utilized here is taken from (Folger et al, 2011). The media simu-
lated in all the analyses throughout the paper is the RPMI-1640
media that was used to grow the cell lines experimentally (Lee
et al, 2007; Choy et al, 2008).
Building cell-specific metabolic models and computing lactate secretion
Our method to reconstruct the NCI-60 cancer cell lines (see Supple-
mentary Material, based on the yet unpublished methods in Yizhak
et al, submitted) required several key inputs: (a) the generic human
model (Duarte et al, 2007), (b) gene expression data for each cancer
cell line from (Lee et al, 2007), and (c) growth rate measurements.
The algorithm then reconstructs a specific metabolic model for each
sample by modifying the upper bounds of growth-associated reac-
tions in accordance with their gene expression (Note: the growth
rates were used only to determine which reactions should be used
in constraining the models, in order to obtain models that were as
physiologically relevant as possible; they were not used to deter-
mine reaction bounds). A similar procedure was used to reconstruct
the lymphoblast metabolic models (Choy et al, 2008) for compari-
son against normal proliferating cells. A more detailed description is
found in the Supplementary Material.
Simulations of the Warburg effect include the examination of
minimal lactate production rate under different demands for
biomass production, glucose, glutamine, and oxygen uptake rates
(Supplementary Material). We examined the minimal value of
lactate secretion as it testifies whether or not the cell is enforced to
secrete lactate under a given condition (Supplementary Fig S1). All
the correlations reported in the paper are Spearman rank correla-
tions and their associated P-values are computed using the exact
permutation distribution.
Calculating wild-type and perturbed lactate secretion rates and
OCR levels
For simulating lactate secretion under normoxic conditions (when
comparing to Jain et al (Jain et al, 2012), Wu et al (Wu et al, 2007)
and the breast cancer data collected in this paper), oxygen maximal
uptake rate was set to the highest value under which minimal
lactate secretion is positive. Since metabolic models are designed to
maximize growth yield rather than growth rate, using an unlimited
amount of oxygen in GSMM simulations will result in a state where
the minimal lactate secretion rate equals zero. However, it’s impor-
tant to note that even under the limited oxygen levels simulated
here, the generic human model doesn’t show lactate secretion (as
opposed to the NCI-60 cancer cell line models described above). For
simulating the hypoxic conditions measured here for the breast
cancer cell lines, we lowered the oxygen maximal uptake rate by
50% of its normoxic state as described above. Under each of these
conditions, we sampled the solution space under maximal biomass
yield and obtained 1,000 feasible flux distributions (Bordel et al,
2010). The predicted lactate secretion rate is the average lactate
secretion flux over these samples. For emulating the perturbation
experiments in Wu et al we gradually lowered the bound of the
corresponding compound target (from the maximal bound to 0)
and repeated the procedure described above for computing
the ECAR (lactate secretion) and the OCR, which in a similar
manner is defined as the average oxygen consumption flux across
all samples.
Calculating the EOR and AFR measures for assessing the Warburg level
of the cell lines and using them to predict drug response
The EOR and AFR measures were calculated in a similar manner to
that described above. Specifically, the EOR is calculated as the mean
over lactate secretion across all samples divided by the mean over
oxygen consumption across all samples. Similarly, the AFR is calcu-
lated as the mean flux carried by the reactions producing ATP in
glycolysis versus the mean flux carried by the reaction producing
ATP in OXPHOS. To determine an empiric P-value in the drug
response analysis we randomly shuffled the drug response data
1,000 times, each time examining the resulting Wilcoxon P-value
over the original set of cell lines.
Predicting the effect of reaction knockouts
Each metabolic reaction in each cell line model is perturbed by
constraining its flux to zero. Under each perturbation the minimal
lactate secretion (under maximal growth rate) and the maximal
growth rate is calculated. The set of reactions that eliminate forced
lactate secretion while maintaining a level of cell growth that is
> 10% of the wild-type growth prediction is further tested for the
AFR level. The mean AFR level for each cell line under each of these
perturbations is calculated over 1,000 flux distribution samples as
described above. The final set of predicted reactions includes those
whose knockout reduces the AFR to below 60% of its wild-type level.
Datasets
Growth rate measurements and drug response data were down-
loaded from the NCI website.
Growth rate: http://dtp.nci.nih.gov/docs/misc/common_files/
cell_list.html
Drug response: http://discover.nci.nih.gov/nature2000/naturein
tromain.jsp
Experimentally measuring lactate secretion rates of breast
cancer cell lines
Cell Culture
The MCF7, T47D, Hs578T and BT549 breast cancer cell lines were
obtained from the American Type Culture Collection and London
Research Institute Cell Services. Cells were cultured in DMEM/F12
(1:1), with 2 mM L-glutamine and penicillin/streptomycin. Medium
was supplemented with 10% FCS (GIBCO) for the cancer cell lines
and 5% horse serum, 20 ng/ml EGF, 5 lg/ml hydrocortisone,
10 lg/ml insulin, and 100 ng/ml cholera toxin for the non-
malignant cell lines.
Lactate secretion measurements
Cells were cultured under normoxic (20% O2) and hypoxic (0.5%
O2) conditions for 72 h. Cells were starved of glucose and glutamine
for 1 h and full medium was added for 1 h. Lactate secretion was
determined from normoxic and hypoxic cells and normalized to
cell growth (increase in total protein during the 72 h incubation in
normoxia). Lactate concentrations in media incubated with or
without cells were determined using lactate assay kits (BioVision).
Total protein content determined by Sulforhodamine B assay was
used for normalization. Two experiments were performed with
three or four biologically independent replicates (total of seven
replicates).
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Cell culture for live cell imaging and cell migration assays
T47D, MCF-7, MDA-MB-435, BT549, MDA-MB-231 and Hs578t were
cultured in RPMI (GIBCO, Life Technologies, Carlsbad, CA, USA)
supplemented with 10% FBS (PAA, Pashing Austria) and 100
International Units/ml penicillin and 100 lg/ml streptomycin
(Invitrogen, Carlsbad, CA, USA).
Gene silencing
Human siRNA SmartPools (a combination of four individual singles)
for the 17 predicted genes were purchased in siGENOME format
from Dharmacon (Lafayette, CO, USA). Plates were diluted to 1 lM
working concentration in complementary 1× siRNA buffer in a
96-well plate format. A non-targeting siRNA was used as negative
control. A 50 nM reverse transfection was performed according to
manufacturer’s guidelines. Complex time was 20 min and 5,000
cells were added. The plate was placed in the incubator overnight
and the medium was refreshed the following morning. After
48–72 h cells were used for various assays. Cell migration and meta-
bolic flux assay experiments were performed in duplicate while the
cell proliferation assay was performed in triplicate.
Live cell imaging random cell migration assay
Glass bottom 96-well plates (Greiner Bio-one, Monroe, NC, USA)
were coated with 20 lg/ll collagen type I (isolated from rat tails)
for 1 h at 37°C. 48 h after silencing, the MDA-MB-231 cells were re-
plated onto the collagen-coated glass bottom plate. 24 h after seed-
ing, cells were pre-exposed for 45 min to 0.1 lg/µl Hoechst 33342
(Fisher Scientific, Hampton, NH, USA) to visualize nuclei. After
refreshing the medium, cells were placed on a Nikon Eclipse
TE2000-E microscope fitted with a 37°C incubation chamber, 20×
objective (0.75 NA, 1.00 WD) automated stage and perfect focus
system. Three positions per well were automatically defined, and
the Differential Interference Contrast (DIC) and Hoechst signals
were acquired with a CCD camera (Pixel size: 0.64 lm) every
20 min for a total imaging period of 12 h using NIS software
(Nikon). All data were converted and analyzed using custom-made
ImagePro Plus macros (Roosmalen et al, 2011). Cell migration was
quantified by tracking nuclei in time. Changes in migration speed
per knockdown were evaluated via a two-sided t-test comparing the
speed for every individual cell followed overtime for 16 h and the
corresponding control values. Data shown are normalized to control
and represent only one replicate. Of note, for all four cell lines both
replicates showed a R2 of reproducibility above 0.75. Genes achiev-
ing P-value < 0.05 after correcting for multiple hypothesis using
FDR with a = 0.05 are considered as hits.
Proliferation assay
Cells were directly transfected and plated onto micro-clear 96-well
plates (Greiner Bio-one). After 5 days of incubation, the cells were
stained with Hoechst 33342 and fixed with TCA (Trichloroacetic
acid) allowing both a nuclear counting and/or Sulforodamine B
(SRB) readout. Whole wells were imaged using epi-fluorescence
and the number of nuclei was determined using a custom-made
ImagePro macro. Plates were further processed for SRB staining as
described earlier (Zhang et al, 2011). SRB data showed a complete
overlap with the nuclear count so this measure is used in all
figures. Changes in proliferation rates upon knockdown when
compared to control were evaluated in triplicate via a two-sided
t-test. The mean proliferation rate after knockdown between all
three replicates was calculated and normalized to the non-targeting
siRNA (= control). Genes achieving P-value < 0.05 after correcting
for multiple hypothesis using FDR with a = 0.05 are considered as
hits.
Metabolic flux assay
The bioenergetics flux of cells in response to gene silencing was
assessed using the Seahorse XF96 extracellular flux analyzer
(Seahorse Bioscience). About 8,000 MDA-MB-231 cells per well
(Seahorse plate) were treated with siRNAs or control for 72 h. Each
gene (in total 7) was knockdown in six different wells and the
experiment was performed twice (so a total of six replicates per
plate and two plates). Prior to measurement, the medium was
replaced with unbuffered DMEM XF assay medium. The basal
oxygen consumption rate (OCR) and extracellular acidification rate
(ECAR) were then determined using the XP96 plate reader with the
standard program as recommended by the manufacturer: three
measurements per well were done (so for each gene 18 measure-
ments were obtained for both OCR and ECAR). After the measure-
ments were completed, the plates were live stained with Hoechst
33342 for 1 h and fixed with TCA allowing both a nuclear counting
and/or SRB readout. Whole wells were imaged using epi-fluores-
cence and the number of nuclei was determined using a custom-
made ImagePro macro. Plates were further processed for SRB stain-
ing as described earlier (Zhang et al, 2011). SRB data showed a
complete overlap with the nuclear count so this measure was used
for normalization. All values are normalized to nuclear count. EOR
for control and each gene knockdown is computed by dividing the
corresponding ECAR and OCR values. A two-sided t-test is applied
to examine significant changes between control and knockdown-
induced EOR.
Supplementary information for this article is available online:
http://msb.embopress.org
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